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Background
The assessment of functional ability is an essential part
of the clinical evaluation of patients with juvenile der-
matomyositis (JDM). However, no physical function tool
specific for JDM is currently available.
Objectives
To develop and validate a new functional ability ques-
t i o n n a i r es p e c i f i cf o rJ D M ,n a m e dJ u v e n i l eM y o s i t i s
Functionality Scale (MyoFun).
Methods
The MyoFun assesses the ability of the child to perform
15 activities that require the use of all skeletal muscles
and muscle groups. Each item is scored from 0 to 3
(0=with no difficulty; 1=with some difficulty; 2=with
much difficulty; 3=unable to do). The total score ranges
from 0 (normal physical function) to 45 (worst physical
function). A parent of 27 children with JDM was asked
to complete the MyoFun and the Childhood Health
Assessment Questionnaire (C-HAQ) and to rate the
child’s overall well-being and pain intensity on a 21-
numbered circle visual analog scale (VAS). The attend-
ing physician assessed the child’s muscle strength/func-
tion with the Kendall’s Manual Muscle Testing (MMT)
and the Childhood Myositis Assessment Scale (CMAS).
Laboratory tests included creatine phosphokinase (CK)
and lactic dehydrogenase (LDH). Construct validity of
the MyoFun was examined by calculating its Spearman’s
correlations with the other JDM outcome measures on
both cross-sectional data and change between 2
consecutive visits. Correlations were considered high,
moderate or low when >0.7, 0.4-0.7, or <0.4, respectively
Results
The MyoFun was found to be feasible, requiring < 5 min-
utes to be completed and < 2 minutes to be scored. The
table shows the Spearman’sc o r r e l a t i o n so ft h eM y o F u n
score with the scores of the other JDM outcome measures.
A second visit made within 6 months from baseline
visit was available for 13 patients. Spearman’sc o r r e l a -
tion between the change in the MyoFun score and the
change in the MMT score was -0.90.
Conclusion
Preliminary validation analyses have shown that the
MyoFun is feasible and has an excellent construct valid-
ity and is, thus, suitable for the assessment of functional
ability in children with JDM.
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Table
MMT CMAS C-HAQ Well-being VAS Pain VAS CK LDH
MyoFun -0.78 -0.66 0.90 0.85 0.89 0.27* 0.43
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